---
schema_version: "secwatch.filing_event.v1"
accession: "0001485003-23-000031"
form_type: "8-K"
ticker: "CARM"
cik: "0001485003"
company_name: "Carisma Therapeutics Inc."
filed_at: "2023-02-07T23:59:59+00:00"
generated_at: "2026-06-19T22:49:23.888396+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sesen Bio merger partner Carisma appoints Moderna CSO Lin Guey to SAB; merger on track for Q1 2023

## Summary
- Carisma Therapeutics appointed Lin Guey, PhD (Chief Scientific Officer of Moderna's External Research Ventures) to its Scientific Advisory Board.
- Dr. Guey oversees Moderna's partnership with Carisma to develop in vivo engineered CAR-M therapies for cancer.
- Merger between Sesen Bio and Carisma expected to close in Q1 2023, subject to stockholder approval and other conditions.
- Carisma expects additional preclinical proof-of-concept data for its CAR-M therapy in Q1 2023.
- Moderna will fully fund R&D for up to 12 oncology targets under its collaboration with Carisma.

## SEC filing metadata
- accession: 0001485003-23-000031
- form_type: 8-K
- ticker: CARM
- cik: 0001485003
- company_name: Carisma Therapeutics Inc.
- filed_at: 2023-02-07T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1485003/000148500323000031/0001485003-23-000031-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1485003/000148500323000031/sesn-20230207.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001485003-23-000031
- JSON: https://secwatch.observer/filing/0001485003-23-000031.json
- Plain text: https://secwatch.observer/filing/0001485003-23-000031.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.